Table 3.

Sensitivity analysis by leave-one-out method

Study excluded	Malignancy	NMSC	Malignancy excluding NMSC	SAE	Death
Burmester [18]	1.42 (0.59, 3.41)	1.44 (0.36, 5.76)	1.12 (0.40, 3.13)	1.12 (0.87, 1.45)	2.03 (0.73, 5.64)
Fleischman [19]	1.97 (0.75, 5.16)	2.01 (0.43, 9.35)	1.53 (0.48, 4.83)	1.14 (0.87, 1.49)	1.70 (0.61, 4.77)
Fleischman [20]	1.24 (0.50, 3.12)	1.18 (0.25, 5.47)	0.99 (0.33, 2.91)	1.21 (0.92, 1.59)	1.76 (0.63, 4.92)
Genovese [21]	1.41 (0.56, 3.53)	1.44 (0.36, 5.76)	1.09 (0.37, 3.21)	1.16 (0.91, 1.49)	1.99 (0.75, 5.27)
Van der Heijde [25]	1.64 (0.65, 4.14)	1.75 (0.36, 8.61)	1.20 (0.40, 3.61)	1.13 (0.88, 1.46)	1.95 (0.64, 5.89)
Kivitz [22]	1.42 (0.59, 3.41)	1.44 (0.36, 5.76)	1.12 (0.40, 3.13)	1.16 (0.90, 1.48)	1.99 (0.75, 5.27)
Kremer [23]	1.43 (0.57, 3.58)	1.49 (0.32, 6.99)	1.12 (0.40, 3.13)	1.16 (0.90, 1.48)	1.99 (0.75, 5.27)
Li [24]	1.42 (0.59, 3.41)	1.44 (0.36, 5.76)	1.12 (0.40, 3.13)	1.15 (0.90, 1.48)	2.37 (0.85, 6.59)
Takeuchi [26]	1.22 (0.48, 3.09)	Not estimated	Not estimated	1.19 (0.93, 1.54)	1.99 (0.75, 5.27)
Tanaka [27]	1.42 (0.59, 3.41)	1.44 (0.36, 5.76)	1.12 (0.40, 3.13)	1.15 (0.90, 1.48)	1.99 (0.75, 5.27)
Taylor [28]	1.17 (0.41, 3.37)	1.02 (0.22, 4.73)	0.99 (0.28, 3.46)	1.12 (0.84, 1.48)	2.51 (0.85, 7.37)
Vollenhoven [29]	1.37 (0.54, 3.43)	1.44 (0.36, 5.76)	1.03 (0.35, 3.08)	1.16 (0.90, 1.50)	1.82 (0.65, 5.05)
Westhovens [30]	1.42 (0.59, 3.41)	1.44 (0.36, 5.76)	1.12 (0.40, 3.13)	1.10 (0.86, 1.42)	1.95 (0.70, 5.43)

NMSC non melanomatous skin cancer, SAE serious adverse events